CAR T-Cell Therapy for Relapsed/Refractory CLL

2 Views
administrator
administrator
07/14/23

The panelists provide insight on the use of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia and the TRANSCEND CLL-004 trial of liso-cel (JCAR017) in relapsed/refractory disease.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next